I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

 I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

Shots:

  • MacroGenics to receive $15M up front, up to $135M as development & regulatory milestones and royalties on sales in Greater China. I-Mab to get development & commercialization rights for Enoblituzumab in China, Hong Kong, Macau and Taiwan
  • As per the agreement, I-Mab will lead global clinical studies including its territories. In H2’19, MacroGenics plans to initiate P-II study of enoblituzumab + MGA012 (licensed to Incyte Corporation) as 1L therapy for head and neck cancer
  • Enoblituzumab is mAb incorporating MacroGenics’ Fc Optimization technology platform that targets B7-H3 which regulates the immune response in multiple cancer. Fc-optimization technology modulates an Ab interaction with immune effector cell affecting the killing of cancer cells through ADCC

Click here to read full press release/ article | Ref: MacroGenics | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post